Speakers

Expand/Collapse

Alexander Ploss
Associate Professor of Molecular Biology
Princeton University

Day One

Tuesday April 26, 2022

2:00 pm | Utility of Animal Models for Evaluating Preclinically Novel HBV Therapeutics

Andrew Vaillant
Chief Scientific Officer
Replicor

Day Two

Wednesday April 27, 2022

9:00 am | Surface Antigen Loss & Transaminase Flares – Critical Milestones for Achieving Functional Cure

Bertrand Georges
Chief Technology Officer
Altimmune

Day Two

Wednesday April 27, 2022

2:00 pm | Illuminating Immunotherapeutics in the Treatment of Chronic Hepatitis B

Carey Hwang
Senior Vice President, Clinical Research, Head of Chronic Infection
Vir Biotechnology

Day One

Tuesday April 26, 2022

11:30 am | The Potential Role of an Anti-HBs Antibody in Combination Therapy to Achieve Functional Cure in Chronic HBV

8:30 am | Panel Discussion: What, When & How? Pursuing Combination Therapy to Improve Durable Efficacy & Decrease Viral Breakthrough

David Anderson
Chief Scientific Officer
VBI Vaccines

Day One

Tuesday April 26, 2022

11:00 am | Clinical Trial Design Considerations for a Combination Therapy with Multiple Mechanisms of Action to Achieve a Functional Cure

8:30 am | Panel Discussion: What, When & How? Pursuing Combination Therapy to Improve Durable Efficacy & Decrease Viral Breakthrough

Day Two

Wednesday April 27, 2022

4:30 pm | Chair’s Closing Remarks & End of Conference

8:25 am | Chair’s Opening Remarks

Francisco Diaz- Mitoma
Chief Medical Officer
VBI Vaccines

Day Two

Wednesday April 27, 2022

8:30 am | Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure

Helmut Brunar
Chief Executive Officer
Viravaxx

Day Two

Wednesday April 27, 2022

3:30 pm | VVX001: A Candidate Vaccine Which Enhances HBV Virus-Specific Immunity In Vivo

Herbert Virgin
Chief Scientific Officer & Executive Vice President of Research
Vir Biotechnology

Day One

Tuesday April 26, 2022

4:00 pm | Chair’s Closing Remarks

8:25 am | Chair’s Opening Remarks

Hubert Trübel
Chief Medical Officer
AiCuris

Day One

Tuesday April 26, 2022

3:00 pm | Translation of Antivirals & Immunostimulants in HBV: From Bench to Bedside

Jeysen Yogaratnam
Chief Medical Officer
Drug Farm

Day Two

Wednesday April 27, 2022

11:00 am | Exploring Immunotherapies in Development to Achieve a Functional Cure for Chronic HBV

Katie Kitrinos
Vice President, Clinical Virology
Assembly Biosciences

Day One

Tuesday April 26, 2022

1:00 pm | From HBV RNA to Core-Related Antigen: Novel Viral Biomarkers to Guide Treatment Management & Clinical Outcome Prediction

Day Two

Wednesday April 27, 2022

8:30 am | Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure

Kees Melief
Chief Scientific Officer
ISA Pharmaceuticals

Day Two

Wednesday April 27, 2022

1:30 pm | Achieving Sustained Treatment Response: The Need for Immunotherapy in Chronic HBV

Linong Zhang
Director
Sanofi Pasteur

Luisa Stamm
Chief Medical Officer
Assembly Biosciences

Day One

Tuesday April 26, 2022

9:00 am | Interrogating Therapeutic Agents with Additive or Synergistic Activity against HBV for Combination Therapy

8:30 am | Panel Discussion: What, When & How? Pursuing Combination Therapy to Improve Durable Efficacy & Decrease Viral Breakthrough

Mark Dybul
Chief Executive Officer
Enochian BioSciences

Day Two

Wednesday April 27, 2022

9:30 am | Eliminating HBV for Sterilizing Cure: Is it Possible?

8:30 am | Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure

Michael Newman
Founder & Chief Scientific Officer
Indaptus Therapeutics

Day Two

Wednesday April 27, 2022

12:00 pm | Driving Pre-Clinical Anti-HBV Activity With a Novel Multi-TLR Agonist Therapeutic Vaccine

Nezam Afdhal
Chief of the Division of Gastroenterology, Hepatology & Nutrition
Beth Israel Deaconess Medical Center

Day One

Tuesday April 26, 2022

9:30 am | Drawing Comparisons with Hepatitis C: Breaking New Ground or Following in the Footsteps?

Patricia Mendez
Head HBV Cure
Gilead Sciences

Day One

Tuesday April 26, 2022

8:30 am | Panel Discussion: What, When & How? Pursuing Combination Therapy to Improve Durable Efficacy & Decrease Viral Breakthrough

Patrick Kennedy
Clinical Professor of Translational Hepatology
Queen Mary University Of London

Day One

Tuesday April 26, 2022

3:30 pm | Rethinking Treatment Thresholds & Patient Subgroups to Implement Targeted Clinical Trials

Day Two

Wednesday April 27, 2022

8:30 am | Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure

Rajan George
Founder, President & Chief Executive Officer
Akshaya Bio

Day Two

Wednesday April 27, 2022

4:00 pm | Chimigen® HBV: An Immunotherapy for Chronic Hepatitis B

Sarah Browne
Senior Director, Clinical Development
Altimmune

Day Two

Wednesday April 27, 2022

3:00 pm | HepTcell as Immunotherapy to Achieve Functional Cure for Chronic HBV

8:30 am | Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure

Shihyun You
Senior Scientific Director
GSK

Day Two

Wednesday April 27, 2022

11:30 am | Bepirovirsen Implying Potential Dual Mechanism of Action

Thomas Baumert
Professor of Medicine, Head Inserm Research Institute, Chair
Hepatology University Hospital

Timothy Block
President
Hepatitis B Foundation

Day One

Tuesday April 26, 2022

1:30 pm | Emerging & Established Non-Invasive Biomarkers for Predicting & Evaluating Efficacy of HBV Therapeutics